PRECIGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
PRECIGEN, INC. (PGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 354.39 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-04
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 283.55K shares, a 58.42% increase year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 70.84K shares, a 84.24% decline year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 6.32K shares, a 98.75% decline year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 338.73K shares, a 21.50% increase year-over-year.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 973.59K shares, a 40.71% decline from fiscal 2024.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 1.64M shares, a 129.17% increase from fiscal 2023.
- PRECIGEN, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 716.55K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 283.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 354.39K shares 10-Q · filed 2026-08-04 | 360.70K shares derived: sum of 3 quarters · filed 2026-08-04 | 699.44K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 70.84K shares 10-Q · filed 2026-05-13 | 77.16K shares derived: sum of 2 quarters · filed 2026-05-13 | 415.89K shares derived: sum of 3 quarters · filed 2026-05-13 | 594.88K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 6.32K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 345.05K shares derived: sum of 2 quarters · filed 2026-03-25 | 524.03K shares derived: sum of 3 quarters · filed 2026-03-25 | 973.59K shares 10-K · filed 2026-03-25 |
| 2025-09-30 | 338.73K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 517.72K shares derived: sum of 2 quarters · filed 2025-11-13 | 967.27K shares 10-Q · filed 2025-11-13 | 1.47M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | 178.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 628.54K shares 10-Q · filed 2025-08-12 | 1.13M shares derived: sum of 3 quarters · filed 2026-03-25 | 1.41M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | 449.55K shares 10-Q · filed 2025-05-14 | 954.87K shares derived: sum of 2 quarters · filed 2026-03-25 | 1.23M shares derived: sum of 3 quarters · filed 2026-03-25 | 1.75M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | 505.31K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 784.10K shares derived: sum of 2 quarters · filed 2026-03-25 | 1.30M shares derived: sum of 3 quarters · filed 2026-03-25 | 1.64M shares 10-K · filed 2026-03-25 |
| 2024-09-30 | 278.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 797.36K shares derived: sum of 2 quarters · filed 2024-11-14 | 1.14M shares 10-Q · filed 2024-11-14 | 1.14M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-06-30 | 518.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 858.00K shares 10-Q · filed 2024-08-14 | 862.25K shares derived: sum of 3 quarters · filed 2026-03-25 | 1.41M shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-03-31 | 339.43K shares 10-Q · filed 2024-05-14 | 343.68K shares derived: sum of 2 quarters · filed 2026-03-25 | 892.55K shares derived: sum of 3 quarters · filed 2026-03-25 | |
| 2023-12-31 | 4.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 553.13K shares derived: sum of 2 quarters · filed 2026-03-25 | 716.55K shares 10-K · filed 2026-03-25 | |
| 2023-09-30 | 548.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 712.30K shares 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | 163.43K shares 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |